Compare WDFC & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WDFC | TNGX |
|---|---|---|
| Founded | 1953 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 2.9B |
| IPO Year | 1995 | 2020 |
| Metric | WDFC | TNGX |
|---|---|---|
| Price | $248.33 | $31.47 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 10 |
| Target Price | ★ $270.00 | $21.78 |
| AVG Volume (30 Days) | 138.9K | ★ 5.5M |
| Earning Date | 04-09-2026 | 05-08-2026 |
| Dividend Yield | ★ 1.91% | N/A |
| EPS Growth | ★ 30.92 | 26.89 |
| EPS | ★ 2.78 | N/A |
| Revenue | ★ $488,109,000.00 | $62,384,000.00 |
| Revenue This Year | $8.23 | N/A |
| Revenue Next Year | $5.85 | N/A |
| P/E Ratio | $88.51 | ★ N/A |
| Revenue Growth | 19.49 | ★ 48.29 |
| 52 Week Low | $175.38 | $4.80 |
| 52 Week High | $253.24 | $34.39 |
| Indicator | WDFC | TNGX |
|---|---|---|
| Relative Strength Index (RSI) | 77.57 | 58.74 |
| Support Level | $189.99 | $19.74 |
| Resistance Level | $250.04 | $34.39 |
| Average True Range (ATR) | 6.76 | 2.49 |
| MACD | 3.22 | -0.05 |
| Stochastic Oscillator | 95.37 | 48.50 |
WD-40 Co is a global marketing organization focused on developing and selling products that solve maintenance and cleaning problems internationally. It offers two product groups: maintenance products, including the flagship WD-40 Multi-Use Product, which serves as a lubricant, rust preventative, penetrant, and moisture displacer, marketed globally; and homecare and cleaning products, mainly sold in North America, the UK, and Australia. The company distributes its products through hardware stores, automotive parts outlets, industrial suppliers, mass retailers, online platforms, and specialty retailers across the Americas, EIMEA, and Asia-Pacific, with the majority of revenue generated in the Americas.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.